SLC5A2 and hydrops fetalis: With large clinical trials indicating a reduced risk of hospitalization for heart failure with SGLT2 inhibitor therapy, the DAPA-HF Trial Committees, and Investigators sought to explore the effect of dapagliflozin use in patients with New York Heart Association (NYHA) class II–IV heart failure and a reduced ejection fraction (≤40%).